US Stock MarketDetailed Quotes
AIM AIM ImmunoTech
- 0.2550
- -0.0150-5.56%
Close Oct 1 16:00 ET
- 0.2890
- +0.0340+13.33%
Post 19:50 ET
14.57MMarket Cap-447P/E (TTM)
0.2672High0.2501Low146.10KVolume0.2649Open0.2700Pre Close37.52KTurnover0.31%Turnover RatioLossP/E (Static)57.14MShares0.620052wk High2.38P/B12.14MFloat Cap0.211252wk Low--Dividend TTM47.60MShs Float836.0000Historical High--Div YieldTTM6.33%Amplitude0.2112Historical Low0.2560Avg Price1Lot Size
AIM ImmunoTech Stock Forum
Sign in to post a comment
$AIM ImmunoTech (AIM.US)$
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
AIM ImmunoTech (NYSE American: AIM) reported positive preliminary data from its Phase 1b/2 study of Ampligen and Imfinzi combination therapy for late-stage pancreatic cancer. The study showed stable disease in two out of three patients at 6 months in the first subject cohort. The combination therapy was generally wel...
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
AIM ImmunoTech (NYSE American: AIM) reported positive preliminary data from its Phase 1b/2 study of Ampligen and Imfinzi combination therapy for late-stage pancreatic cancer. The study showed stable disease in two out of three patients at 6 months in the first subject cohort. The combination therapy was generally wel...
1
1
$AIM ImmunoTech (AIM.US)$ Reuters
2 mins ago
AIM ImmunoTech Announces Print Publication and Further Positive Findings From a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
2 mins ago
AIM ImmunoTech Announces Print Publication and Further Positive Findings From a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
$AIM ImmunoTech (AIM.US)$ Aim Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
1
$AIM ImmunoTech (AIM.US)$ AIM ImmunoTech Announces First Dose Level Is Generally Well-Tolerated in Phase 1B/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
5
$AIM ImmunoTech (AIM.US)$
NEWS
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
AIM ImmunoTech Inc. announced promising interim data showing that combining Ampligen with Keytruda in treating recurrent ovarian cancer could have a powerful synergistic effect, significantly increasing response rates and progression-free survival. The study also highlighted increased an...
NEWS
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
AIM ImmunoTech Inc. announced promising interim data showing that combining Ampligen with Keytruda in treating recurrent ovarian cancer could have a powerful synergistic effect, significantly increasing response rates and progression-free survival. The study also highlighted increased an...
2
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Fomo Mofo : none of these really look that good to me today... maybe something will come up when the markets open. thank you for the useful information
Sabrina Fan : What are these symbolizing? Greatest change in price?
Stock_Drift OP Sabrina Fan : And % change,volume and float.
mark mark8 : What software are you using to view the pictures?